Genomic instability and histone H3 phosphorylation induction by the Ras-mitogen activated protein kinase pathway in pancreatic cancer cells

International Journal of Cancer

Volumn 124, Issue 3, 2009, Pages 562-567

  Espino, Paula S ^a   Pritchard, Susan ^a   Heng, Henry H Q ^b   Davie, James R ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

H3 phosphorylation; Nonclonal chromosome aberrations; Pancreatic cancer; Ras MAPK pathway; Spectral karyotyping

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; HISTONE H3; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE; RAS PROTEIN; HISTONE;

ARTICLE; CHROMOSOME ABERRATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME PHOSPHORYLATION; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; GENETIC EPIGENESIS; GENETICS; METABOLISM; MUTATION; ONCOGENE RAS; PANCREAS TUMOR; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; EPIGENESIS, GENETIC; GENES, RAS; GENOMIC INSTABILITY; HISTONES; HUMANS; MAP KINASE SIGNALING SYSTEM; MUTATION; PANCREATIC NEOPLASMS; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 58149280831     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23959     Document Type: Article

References (37)

1. Dunn KL, Espino P, Drobic B, He S, Davie JR. The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling. Biochem Cell Biol 2005;83:1-14.
2. Langst G, Becker PB. Nucleosome remodeling: one mechanism, many phenomena? Biochim Biophys Acta 2004;1677:58-63.
3. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
4. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26:3291-310.
5. Maitra A, Kern SE, Hruban RH. Molecular pathogenesis of pancreatic cancer. Best Pract Res Clin Gastroenterol 2006;20:211-26.
6. Hazzalin CA, Mahadevan LC. MAPK-regulated transcription: a continuously variable gene switch? Nat Rev Mol Cell Biol 2002;3:30-40.
7. Reul JM, Chandramohan Y. Epigenetic mechanisms in stress-related memory formation. Psychoneuroendocrinology 2007;32(Suppl 1):S21-5.
8. Chadee DN, Hendzel MJ, Tylipski CP, Allis CD, Bazett-Jones DP, Wright JA, Davie JR. Increased Ser-10 phosphorylation of histone H3 in mitogen-stimulated and oncogene-transformed mouse fibroblasts. J Biol Chem 1999;274:24914-20.
9. Dyson MH, Thomson S, Inagaki M, Goto H, Arthur SJ, Nightingale K, Iborra FJ, Mahadevan LC. MAP kinase-mediated phosphorylation of distinct pools of histone H3 at S10 or S28 via mitogen- and stress-activated kinase 1/2. J Cell Sci 2005;118:2247-59.
10. Espino PS, Li L, He S, Yu J, Davie JR. Chromatin modification of the trefoil factor 1 gene in human breast cancer cells by the Ras/mitogen-activated protein kinase pathway. Cancer Res 2006;66:4610-6.
11. Sun JM, Chen HY, Espino PS, Davie JR. Phosphorylated serine 28 of histone H3 is associated with destabilized nucleosomes in transcribed chromatin. Nucleic Acids Res 2007;35:6640-7.
12. Soloaga A, Thomson S, Wiggin GR, Rampersaud N, Dyson MH, Hazzalin CA, Mahadevan LC, Arthur JS. MSK2 and MSK1 mediate the mitogen- and stress-induced phosphorylation of histone H3 and HMG-14. EMBO J 2003;22:2788-97.
13. Dunn KL, Davie JR. Stimulation of the Ras-MAPK pathway leads to independent phosphorylation of histone H3 on serine 10 and 28. Oncogene 2005;24:3492-502.
14. Bode AM, Dong Z. Inducible covalent posttranslational modification of histone H3. Sci STKE 2005:re4.
15. Mahadevan D, von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 2007;6:1186-97.
16. Strelkov IS, Davie JR. Ser-10 phosphorylation of histone H3 and immediate early gene expression in oncogene-transformed mouse fibroblasts. Cancer Res 2002;62:75-8.
17. Drobic B, Espino PS, Davie JR. MSK1 activity and histone H3 phosphorylation in oncogene-transformed mouse fibroblasts. Cancer Res 2004;64:9076-9.
18. Choi HS, Choi BY, Cho YY, Mizuno H, Kang BS, Bode AM, Dong Z. Phosphorylation of histone H3 at serine 10 is indispensable for neoplastic cell transformation. Cancer Res 2005;65:5818-27.
19. Kim HG, Lee KW, Cho YY, Kang NJ, Oh SM, Bode AM, Dong Z. Mitogen- and stress-activated kinase 1-mediated histone H3 phosphorylation is crucial for cell transformation. Cancer Res 2008;68:2538-47.
20. Warner SL, Munoz RM, Stafford P, Koller E, Hurley LH, von Hoff DD, Han H. Comparing aurora A and aurora B as molecular targets for growth inhibition of pancreatic cancer cells. Mol Cancer Ther 2006;5:2450-8.
21. Mai S, Wiener F. The impact of p53 loss on murine plasmacytoma development. Chromosome Res 2002;10:239-51.
22. Benedek K, Chudoba I, Klein G, Wiener F, Mai S. Rearrangements of the telomeric region of mouse chromosome 11 in Pre-B ABL/MYC cells revealed by mBANDing, spectral karyotyping, and fluorescence in-situ hybridization with a subtelomeric probe. Chromosome Res 2004;12:777-85.
23. Fest T, Guffei A, Williams G, Silva S, Mai S. Uncoupling of genomic instability and tumorigenesis in a mouse model of Burkitt's lymphoma expressing a conditional box II-deleted Myc protein. Oncogene 2005;24:2944-53.
24. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363:1049-57.
25. Heng HH, Bremer SW, Stevens J, Ye KJ, Miller F, Liu G, Ye CJ. Cancer progression by non-clonal chromosome aberrations. J Cell Biochem 2006;98:1424-35.
26. Heng HH, Liu G, Bremer S, Ye KJ, Stevens J, Ye CJ. Clonal and nonclonal chromosome aberrations and genome variation and aberration. Genome 2006;49:195-204.
27. Heng HH, Stevens JB, Liu G, Bremer SW, Ye KJ, Reddy PV, Wu GS, Wang YA, Tainsky MA, Ye CJ. Stochastic cancer progression driven by non-clonal chromosome aberrations. J Cell Physiol 2006;208:461-72.
28. Ye CJ, Liu G, Bremer SW, Heng HH. The dynamics of cancer chromosomes and genomes. Cytogenet Genome Res 2007;118:237-46.
29. Bayani J, Selvarajah S, Maire G, Vukovic B, Al-Romaih K, Zielenska M, Squire JA. Genomic mechanisms and measurement of structural and numerical instability in cancer cells. Semin Cancer Biol 2007;17:5-18.
30. Heng HH. Cancer genome sequencing: the challenges ahead. Bio Essays 2007;29:783-94.
31. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995;80:179-85.
32. Lorenzo PS, Kung JW, Bottorff DA, Garfield SH, Stone JC, Blumberg PM. Phorbol esters modulate the Ras exchange factor RasGRP3. Cancer Res 2001;61:943-9.
33. Heeger S. Targeted therapy of the epidermal growth factor receptor in the treatment of pancreatic cancer. Recent Results Cancer Res 2008;177:131-6.
34. de Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, Aldinucci D, Pinto A, Normanno N. The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 2008;214:559-67.
35. Friday BB, Adjei AA. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 2008;14:342-6.
36. Stephens B, Han H, Hostetter G, Demeure MJ, von Hoff DD. Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells. Mol Cancer Ther 2008;7:202-10.
37. Wu C, Sun M, Liu L, Zhou GW. The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene 2003;306:1-12.